Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma

Journal of Nuclear Medicine

Volumn 38, Issue 9, 1997, Pages 1362-1368

  Muratet, Jean Pierre ^a   Giraud, Philippe ^a   Daver, Alain ^a   Minier, Jean François ^a   Gamelin, Erik ^a   Larra, Francis ^a  

^a CENTRE PAUL PAPIN   (France)

Author keywords

Iodine 131 treatment; Thyroglobulin; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME;

EID: 0030983929     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 1978;8:79-84.
2. Krishnamurthy GT, Blahd WH. Radioiodine iodine-131 therapy in the management of thyroid cancer: a prospective study. Cancer 1978;40:195-202.
3. Beienwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of ablation of thyroid remnants with iodine-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984;25:1287-1293.
4. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063-1075.
5. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
6. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well-differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720.
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
8. Schlumberger M, Charbord P, Fragu P, Lumbroso J, Parmentier C, Tubiana M. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyroglobulin levels. J Clin Endocrinol Metab 1980;51:513-519.
9. Schneider AB, Line BR, Goldman JM, et al. Sequential serum thyroglobulin determinations, iodine-131 scans and iodine-131 uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 1981;53:1199-1206.
10. Blahd WH, Drickman MV, Porter CW, Hill VA, Baumgartner WA. Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication. J Nucl Med 1984;25:673-676.
11. Aiello DP, Manni A. Thyroglobulin measurement versus iodine-131 total-body scan for follow-up of well-differentiated thyroid cancer. Arch Int Med 1990;150:437-439.
12. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990;31:1766-1771.
13. Clarke SEM. Radionuclide therapy of the thyroid. Eur J Nucl Med 1991;18:984-991.
14. Block MA, Dailey GE III, Muchmore D. Avoiding reoperation for indeterminate thyroid nodules identified as malignant after surgery. Arch Surg 1991;126:598-602.
15. Burmeister LA, du Cret RP, Mariash CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med 1991;90:217-222.
16. Arad E, O'Mara RE, Wilson GA. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma. Clin Nucl Med 1993;18:662-663.
17. Ley PB, Roberts JW, Symmonds RE Jr, et al. Safety and efficacy of total thyroidectomy for well-differentiated thyroid carcinoma: a 20-year review. Am Surg 1993;59:110-114.
18. DiRusso G, Kern KA. Comparative analysis of complications from iodine-131 radioablation for well-differentiated thyroid cancer. Surgery 1994;116:1024-1030.
19. Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994;67:1127-1131.
20. Matsushita T, Toyota S, Katoh N, Nakagawa T. Iodine-131 treatment of thyroid cancer: relation between effective half-life and efficacy of treatment. Radiat Med 1994;12:167-170.
21. Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994;35:1944-1950.
22. Leung SF, Law MW, Ho SK. Efficacy of low-dose iodine-131 ablation of postoperative thyroid remnants: a study of 69 patients. Br J Radiol 1992;65:905-909.
23. Comtois R, Theriault C, Del-Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993;34:1927-1930.
24. Flower MA, Schlesinger T, Hinton PJ, et al. Radiation dose assessment in radioiodine therapy: 2. practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol 1989;15:345-357.
25. O'Connell ME, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy: dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993;28:16-26.
26. Ramakrishnan N, McClain DE, Catravas GN. Membranes as sensitive targets in thymocyte apoptosis. Int J Radiat Biol 1993;63:693-701.
27. Cramp WA, Yatvin MB, Harms-Ringdahl M. Recent developments in the radiobiology of cellular membranes. Acta Oncol 1994;33:945-952.
28. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
29. Maxon HR, Englaro EE, Thomas SR, et al. Iodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-1136.
30. Wolf JI. The active transport system. In: Leclere J, Orgiazzi J, Rousset B, Schlienger JL, Wemeau JL, eds. La thyroïde. Paris: Expansion Scientifique Française; 1992:17-24.
31. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986;13:277-279.
32. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
33. Kim CK, Tse K, San Pedro E, Alavi A. Influence of various scanning doses on subsequent iodine-131 ablation of thyroid remnants [Abstract]. J Nucl Med 1994;35:14P.
34. Van Herle AJ, Van Herle IS, Greipel MA. An international cooperating study evaluating serum thyroglobulin standards. J Clin Endocrinol Metab 1985;60:338-343.
35. Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 1988;11:175-181.
36. Blahd WH. Serum thyroglobulin in thyroid cancer management. J Nucl Med 1990;31:1771-1773.
37. Marquet PY, Daver A, Sapin R, et al. Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Clin Chem 1996;42:258-262.